[go: up one dir, main page]

CR20200403A - Macrociclos como moduladores del regular de conductancia transmenbrana de la fibrosis quística, composiciones farmacéuticas de estos, su uso en el tratamiento de la fibrosisquística y procesos para elaborarlos - Google Patents

Macrociclos como moduladores del regular de conductancia transmenbrana de la fibrosis quística, composiciones farmacéuticas de estos, su uso en el tratamiento de la fibrosisquística y procesos para elaborarlos

Info

Publication number
CR20200403A
CR20200403A CR20200403A CR20200403A CR20200403A CR 20200403 A CR20200403 A CR 20200403A CR 20200403 A CR20200403 A CR 20200403A CR 20200403 A CR20200403 A CR 20200403A CR 20200403 A CR20200403 A CR 20200403A
Authority
CR
Costa Rica
Prior art keywords
making
pharmaceutical compositions
macrocycles
modulators
treatment
Prior art date
Application number
CR20200403A
Other languages
English (en)
Inventor
Johnny Uy
Prasuna Paraselli
Clara Kuang-Ju Hsia
Jeremy J Clemens
Weichao George Chen
Jason Mccartney
Mark Thomas Miller
Corey Don Anderson
Bryan Frieman
Fabrice Pierre
Anton V Gulevich
Andreas Termin
Thomas Cleveland
Timothy Richard Coon
Senait G Ghirmai
Peter Grootenhuis
Ping Kang
Sara E Swift
Carl V Vogel
Ruah Sara Sabina Hadida
Alexander Russell Abela
Brett B Busch
Haripada Khatuya
Jinglan Zhou
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65529899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20200403(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of CR20200403A publication Critical patent/CR20200403A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

<p>Se revelan compuestos de la fórmula (I): sus sales farmacéuticamente aceptables, derivados deuterados de cualquiera de los anteriores y metabolitos de cualquiera de los anteriores. También se revelan composiciones farmacéuticas que los comprenden, métodos de tratamiento de fibrosis quística que los usan y métodos para prepararlos.</p> <p> </p>
CR20200403A 2018-02-15 2019-02-14 Macrociclos como moduladores del regular de conductancia transmenbrana de la fibrosis quística, composiciones farmacéuticas de estos, su uso en el tratamiento de la fibrosisquística y procesos para elaborarlos CR20200403A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862631453P 2018-02-15 2018-02-15
PCT/US2019/018042 WO2019161078A1 (en) 2018-02-15 2019-02-14 Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them

Publications (1)

Publication Number Publication Date
CR20200403A true CR20200403A (es) 2020-10-26

Family

ID=65529899

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200403A CR20200403A (es) 2018-02-15 2019-02-14 Macrociclos como moduladores del regular de conductancia transmenbrana de la fibrosis quística, composiciones farmacéuticas de estos, su uso en el tratamiento de la fibrosisquística y procesos para elaborarlos

Country Status (39)

Country Link
US (3) US11066417B2 (es)
EP (2) EP4198037A1 (es)
JP (3) JP7214743B2 (es)
KR (1) KR102482271B1 (es)
CN (2) CN117285547A (es)
AR (1) AR114254A1 (es)
AU (2) AU2019222758B2 (es)
BR (1) BR112020015509A2 (es)
CA (1) CA3088577A1 (es)
CL (1) CL2020002055A1 (es)
CR (1) CR20200403A (es)
DK (1) DK3752510T3 (es)
DO (1) DOP2023000016A (es)
EA (1) EA202091930A1 (es)
EC (1) ECSP20053845A (es)
ES (1) ES2939775T3 (es)
FI (1) FI3752510T3 (es)
GE (1) GEP20237571B (es)
HR (1) HRP20230030T1 (es)
HU (1) HUE061046T2 (es)
IL (2) IL294042A (es)
JO (1) JOP20200178A1 (es)
LT (1) LT3752510T (es)
MA (1) MA51828B1 (es)
MD (1) MD3752510T2 (es)
MX (1) MX2020008268A (es)
PE (1) PE20210454A1 (es)
PL (1) PL3752510T3 (es)
PT (1) PT3752510T (es)
RS (1) RS64018B1 (es)
SA (1) SA520412634B1 (es)
SG (1) SG11202006614VA (es)
SI (1) SI3752510T1 (es)
SM (1) SMT202300043T1 (es)
TW (2) TWI780304B (es)
UA (1) UA126304C2 (es)
UY (1) UY38093A (es)
WO (1) WO2019161078A1 (es)
ZA (1) ZA202004357B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117285547A (zh) 2018-02-15 2023-12-26 弗特克斯药品有限公司 作为cftr的调节剂的大环化合物、其药物组合物、它们的用途和制备方法
DK3880197T3 (da) * 2018-11-14 2023-03-27 Vertex Pharma Fremgangsmåder til behandling for cystisk fibrose
MX2021007592A (es) * 2018-12-21 2021-08-11 Novartis Ag Compuestos macrociclicos y su uso en el tratamiento de enfermedades.
TWI867024B (zh) * 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
CN114585628B (zh) * 2019-08-14 2024-03-26 弗特克斯药品有限公司 囊性纤维化跨膜传导调节因子的调节剂
MX2022001828A (es) * 2019-08-14 2022-06-08 Vertex Pharma Formas cristalinas de moduladores del regulador de conductancia transmembrana de la fibrosis quistica (cftr).
TW202120517A (zh) * 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
CN110551077B (zh) * 2019-09-24 2023-01-31 新乡市润宇新材料科技有限公司 一种光催化分子氧氧化制备n-叔丁基-2-苯并噻唑亚磺酰胺的方法
BR112022009202A2 (pt) 2019-11-12 2022-09-06 Genzyme Corp Heteroarilaminosulfonamidas de 6 membros para tratamento de doenças e condições mediadas por atividade deficiente de cftr
WO2021113806A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
WO2021113809A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
WO2022194399A1 (en) 2020-07-13 2022-09-22 Idorsia Pharmaceuticals Ltd Macrocycles as cftr modulators
CA3188787A1 (en) 2020-08-13 2022-02-17 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
WO2022076618A1 (en) * 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4225761A1 (en) * 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076621A1 (en) * 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
KR20230104618A (ko) * 2020-10-07 2023-07-10 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막관통 전도도 조절자의 조절제
CR20230198A (es) * 2020-10-07 2023-07-03 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
EP4225763A1 (en) * 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
BR112023006470A2 (pt) * 2020-10-07 2023-09-26 Vertex Pharma Moduladores de regulador de condutância transmembrana de fibrose cística
PE20231380A1 (es) * 2020-11-18 2023-09-07 Vertex Pharma Macrociclicos que contienen una anillo de 1,3,4-oxadiazol para su uso como moduladores del regulador de la conductancia transmembrana de la fibrosis quistica
WO2022125826A1 (en) 2020-12-10 2022-06-16 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
KR20240155228A (ko) 2022-02-03 2024-10-28 버텍스 파마슈티칼스 인코포레이티드 (6a,12a)-17-아미노-12-메틸-6,15-비스(트리플루오로메틸)-13,19-디옥사-3,4,18-트리아자트리시클로[12.3.1.12,5]노나데카-1(18),2,4,14,16-펜타엔-6-올의 결정질 형태를 제조하는 방법
EP4472635A1 (en) 2022-02-03 2024-12-11 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN118974059A (zh) 2022-02-08 2024-11-15 弗特克斯药品有限公司 囊性纤维化跨膜传导调控因子的调节剂
IL315715A (en) * 2022-04-06 2024-11-01 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulation
WO2023224931A1 (en) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2023224924A1 (en) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Solid forms of a macrocyclic compounds as cftr modulators and their preparation
AU2023338225A1 (en) * 2022-09-07 2025-03-20 Genzyme Corporation Macrocyclic compounds, compositions, and methods of using thereof
WO2024054845A1 (en) * 2022-09-07 2024-03-14 Sionna Therapeutics Macrocycic compounds, compositions, and methods of using thereof
TW202421102A (zh) 2022-09-15 2024-06-01 瑞士商愛杜西亞製藥有限公司 巨環cftr調節劑與cftr校正子及/或cftr增效劑之組合
WO2024056798A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Macrocyclic cftr modulators
TW202421636A (zh) 2022-09-15 2024-06-01 瑞士商愛杜西亞製藥有限公司 (3S,7S,10R,13R)-13-苄基-20-氟-7-異丁基-N-(2-(3-甲氧基-1,2,4-㗁二唑-5-基)乙基)-6,9-二甲基-1,5,8,11-四側氧基-10-(2,2,2-三氟乙基)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-十四氫-[1]㗁[4,7,10,14]四氮雜環十七烷并[16,17-f]喹啉-3-甲醯胺的晶型
CN115536493A (zh) * 2022-10-20 2022-12-30 海门瑞一医药科技有限公司 一种制取3,3,3-三氟甲基-2,2-二甲基丙烷醇的简单方法

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2677682A (en) 1951-08-24 1954-05-04 American Cyanamid Co Sulfonamido pteridines
ID18983A (id) 1996-12-04 1998-05-28 Lilly Co Eli Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
CA2465597A1 (en) 2001-11-14 2003-06-12 Ben Zion Dolitzky Amorphous and crystalline forms of losartan potassium and process for their preparation
MXPA06005343A (es) 2003-11-14 2006-07-10 Vertex Pharma Tiazoles y oxazoles utiles como moduladores de transportadores con cassette de union a atp.
EP3219709B1 (en) 2004-01-30 2020-03-18 Vertex Pharmaceuticals Incorporated Intermediate compound of modulators of atp-binding cassette transporters
DK2502911T3 (en) 2004-06-24 2017-06-06 Vertex Pharma Modulators of ATP-binding cassette transporters
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
CA2618057A1 (en) 2005-08-11 2007-02-22 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2007053641A2 (en) 2005-11-01 2007-05-10 Mars, Incorporated A-type procyanidins and inflammation
CA2635214A1 (en) 2005-12-27 2007-07-05 Vertex Pharmaceuticals Incorporated Compounds useful in cftr assays and methods therewith
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
CN101395147B (zh) 2005-12-28 2013-05-29 弗特克斯药品有限公司 作为atp-结合盒转运蛋白调节剂用于治疗囊性纤维化的1-(苯并[d][1,3]间二氧杂环戊烯-5-基)-n-(苯基)环丙烷-甲酰胺衍生物及相关化合物
EP2007756B1 (en) 2006-04-07 2015-08-26 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
CN101478964B (zh) 2006-05-12 2012-02-29 沃泰克斯药物股份有限公司 N-[2,4-双(1,1-二甲基乙基)-5-羟苯基]-1,4-二氢-4-氧代喹啉-3-羧酰胺的组合物
AU2007351454B2 (en) 2006-11-03 2013-07-18 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
BRPI0811065A2 (pt) 2007-06-08 2014-12-02 Abbott Lab Indazóis 5-heteroaril substituídos como inibidores de quinase
NZ583848A (en) 2007-09-14 2012-07-27 Vertex Pharma Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
PT2231606E (pt) 2007-12-07 2013-05-17 Vertex Pharma Processos para a produção de ácidos cicloalquilcarboxiamido-piridina benzóicos
ES2993060T3 (en) 2007-12-07 2024-12-20 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
CA2716109C (en) 2008-02-28 2016-07-19 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
EP3842037A1 (en) 2008-08-13 2021-06-30 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
AU2009296271A1 (en) 2008-09-29 2010-04-01 Vertex Pharmaceuticals Incorporated Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US8513282B2 (en) 2008-10-23 2013-08-20 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
MX2011004832A (es) 2008-11-06 2011-07-28 Vertex Pharma Moduladores de transportadores de casete de unión a atp.
UA104876C2 (uk) 2008-11-06 2014-03-25 Вертекс Фармасьютікалз Інкорпорейтед Модулятори atф-зв'язувальних касетних транспортерів
RU2543714C2 (ru) 2009-03-20 2015-03-10 Вертекс Фармасьютикалз Инкорпорейтед Способ получения модуляторов регулятора трансмембранной проводимости кистозного фиброза
AU2010310449A1 (en) 2009-10-22 2012-05-03 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
EP3037415A1 (en) 2010-03-19 2016-06-29 Vertex Pharmaceuticals Inc. Solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
RU2711481C2 (ru) 2010-03-25 2020-01-17 Вертекс Фармасьютикалз Инкорпорейтед ТВЕРДЫЕ ФОРМЫ (R)-1-(2, 2-ДИФТОРБЕНЗО[d][1, 3]ДИОКСОЛ-5-ИЛ)-N-(1-(2, 3-ДИГИДРОКСИПРОПИЛ)-6-ФТОР-2-(1-ГИДРОКСИ-2-МЕТИЛПРОПАН-2-ИЛ)-1H-ИНДОЛ-5-ИЛ)ЦИКЛОПРОПАНКАРБОКСАМИДА
HUE056525T2 (hu) 2010-04-07 2022-02-28 Vertex Pharma 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)ciklopropánkarboxamido)-3-metilpiridin-2-il)benzoesav gyógyszerészeti készítményei és azok adagolása
DK2555754T3 (en) 2010-04-07 2016-04-18 Vertex Pharma Solid forms of 3- (6- (1- (2,2-difluoro-benzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) -benzoic acid
CA2796642A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
EP3381899B1 (en) 2010-04-22 2021-01-06 Vertex Pharmaceuticals Incorporated Intermediate compound for process of producing cycloalkylcarboxamido-indole compounds
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
EP2608779A2 (en) 2010-08-23 2013-07-03 Vertex Pharmaceuticals Incorporated Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
BR112013004130A2 (pt) 2010-08-27 2016-07-05 Vertex Pharma composição farmacêutica e administrações da mesma
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
US9034879B2 (en) * 2011-09-16 2015-05-19 Novartis Ag Heterocyclic compounds for the treatment of CF
CA2855019A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
WO2013070961A1 (en) 2011-11-08 2013-05-16 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
DK2806859T3 (da) 2012-01-25 2019-08-05 Vertex Pharma Formuleringer af 3-(6-(1-(2.2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre
BR112014021090B1 (pt) 2012-02-27 2023-01-24 Vertex Pharmaceuticals Incorporated Composição farmacêutica e uso de n-[2,4-bis(1,1-dimetiletil)-5-hidróxifenil]-1,4-di-hidro-4-oxoquinolina3-carboxamida na preparação da mesma
WO2013158121A1 (en) 2012-04-20 2013-10-24 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
GB201207406D0 (en) 2012-04-27 2012-06-13 Glaxo Group Ltd Novel compounds
CN104718188B (zh) 2012-05-22 2018-08-21 基因泰克公司 N-取代的苯甲酰胺类及其在治疗疼痛中的用途
WO2013185112A1 (en) 2012-06-08 2013-12-12 Vertex Pharmaceuticals Incorporated Pharmaceuticl compositions for the treatment of cftr -mediated disorders
EP2872122A1 (en) 2012-07-16 2015-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
CN103571906B (zh) 2012-07-27 2018-12-11 上海泽元海洋生物技术有限公司 一种利用微藻高效生产虾青素的新方法
SG11201503365YA (en) 2012-11-02 2015-06-29 Vertex Pharma Pharmaceutical compositions for the treatment of cftr mediated diseases
MY178621A (en) 2012-11-19 2020-10-19 Vertex Pharmaceuticals Europe Ltd Deuterated cftr potentiators
WO2015051043A1 (en) 2013-10-01 2015-04-09 Amgen Inc. Biaryl acyl-sulfonamide compounds as sodium channel inhibitors
SI3068392T1 (sl) 2013-11-12 2021-07-30 Vertex Pharmaceuticals Incorporated Postopek za pripravo farmacevtskih sestavkov za zdravljenje bolezni, ki jih posreduje CFTR
CA2944140C (en) 2014-04-15 2022-10-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
PL3203840T3 (pl) * 2014-10-06 2021-01-11 Vertex Pharmaceuticals Incorporated Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa
RU2749213C2 (ru) 2014-10-07 2021-06-07 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
ES2882656T3 (es) 2014-11-18 2021-12-02 Vertex Pharma Proceso para realizar pruebas de alto rendimiento de cromatografía líquida de alta resolución
CA2981495C (en) 2015-03-31 2023-09-26 Vertex Pharmaceuticals (Europe) Limited Deuterated vx-661
WO2017053455A1 (en) 2015-09-21 2017-03-30 Concert Pharmaceuticals, Inc. Administration of deuterated cftr potentiators
EP3436432B1 (en) 2016-03-30 2021-01-27 Genentech, Inc. Substituted benzamides and methods of use thereof
US10738030B2 (en) 2016-03-31 2020-08-11 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
KR102448404B1 (ko) 2016-04-07 2022-09-27 프로테오스타시스 테라퓨틱스, 인크. 규소 원자 함유 이바카프터 유사체
MX2018013002A (es) 2016-04-26 2019-01-31 Abbvie Sarl Moduladores de la proteina reguladora de la conductancia transmembrana de la fibrosis quistica.
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
WO2017223188A1 (en) 2016-06-21 2017-12-28 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
WO2018064632A1 (en) 2016-09-30 2018-04-05 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US20190248779A1 (en) 2016-10-26 2019-08-15 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
US20190248765A1 (en) 2016-10-26 2019-08-15 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
EP3532461A1 (en) 2016-10-26 2019-09-04 Proteostasis Therapeutics, Inc. N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis
AU2017352206B2 (en) 2016-10-27 2022-03-03 Vertex Pharmaceuticals (Europe) Limited Methods of treatment with deuterated CFTR potentiators
PL3541390T3 (pl) 2016-11-18 2024-09-09 Cystic Fibrosis Foundation Pirolopirymidyny jako potencjatory cftr
EP3812379A1 (en) 2016-12-09 2021-04-28 Vertex Pharmaceuticals Incorporated Crystalline form of a n-(pyrazol-4-yl)sulfonyl-6-(pyrazol-1-yl)-2-(pyrrolidin-1-yl)pyridine-3-carboxamide for treating cystic fibrosis
AU2017378324B2 (en) 2016-12-16 2021-09-02 Cystic Fibrosis Foundation Bycyclic heteroaryl derivatives as CFTR potentiators
EP3558982A1 (en) 2016-12-20 2019-10-30 AbbVie S.À.R.L. Deuterated cftr modulators and methods of use
CN110177788B (zh) 2017-01-07 2023-03-24 重庆复创医药研究有限公司 作为bcl-2选择性凋亡诱导剂的化合物
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
US20180280349A1 (en) 2017-03-28 2018-10-04 Vertex Pharmaceuticals Incorporated Methods of treating cystic fibrosis in patients with residual function mutations
RU2019133646A (ru) 2017-03-30 2021-04-30 Ф. Хоффманн-Ля Рош Аг Изохинолины в качестве ингибиторов hpk1
EP3615528B1 (en) 2017-04-28 2022-02-16 Proteostasis Therapeutics, Inc. 4-sulfonylaminocarbonylquinoline derivatives for increasing cftr activity
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CA3068609A1 (en) 2017-07-01 2019-01-10 Vertex Pharmaceuticals Incorporated Compositions and methods for treatment of cystic fibrosis
AU2018300150A1 (en) 2017-07-11 2020-01-30 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
CA3069226A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CA3069225A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
EP3662079A4 (en) 2017-07-31 2021-04-14 Technion Research & Development Foundation Limited METHODS OF DETECTION OF MODIFIED AND NON-MODIFIED DNA
JP7121794B2 (ja) 2017-08-02 2022-08-18 バーテックス ファーマシューティカルズ インコーポレイテッド ピロリジン化合物を調製するためのプロセス
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
AU2018346602B2 (en) 2017-10-06 2024-10-17 Proteostasis Therapeutics, Inc. Compounds, compositions and methods for increasing CFTR activity
TWI719349B (zh) 2017-10-19 2021-02-21 美商維泰克斯製藥公司 Ｃｆｔｒ調節劑之結晶形式及組合物
US20210228489A1 (en) 2017-12-04 2021-07-29 Vertex Pharmaceuticals Incorporated Compositions for treating cystic fibrosis
CA3085006A1 (en) 2017-12-08 2019-06-13 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
CN117285547A (zh) 2018-02-15 2023-12-26 弗特克斯药品有限公司 作为cftr的调节剂的大环化合物、其药物组合物、它们的用途和制备方法
WO2019191620A1 (en) 2018-03-30 2019-10-03 Vertex Pharmaceuticals Incorporated Crystalline forms of modulators of cftr
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
DK3880197T3 (da) 2018-11-14 2023-03-27 Vertex Pharma Fremgangsmåder til behandling for cystisk fibrose
MX2021007592A (es) 2018-12-21 2021-08-11 Novartis Ag Compuestos macrociclicos y su uso en el tratamiento de enfermedades.
EP3921313A1 (en) 2019-02-06 2021-12-15 Novartis AG N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
US20220160705A1 (en) 2019-03-20 2022-05-26 Cornell University Methods for controlling prostaglandin-mediated biological processes
AR118555A1 (es) 2019-04-03 2021-10-20 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2020214921A1 (en) 2019-04-17 2020-10-22 Vertex Pharmaceuticals Incorporated Solid forms of modulators of cftr
WO2020242935A1 (en) 2019-05-29 2020-12-03 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
CN114585628B (zh) 2019-08-14 2024-03-26 弗特克斯药品有限公司 囊性纤维化跨膜传导调节因子的调节剂
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
MX2022001828A (es) 2019-08-14 2022-06-08 Vertex Pharma Formas cristalinas de moduladores del regulador de conductancia transmembrana de la fibrosis quistica (cftr).
BR112022009202A2 (pt) 2019-11-12 2022-09-06 Genzyme Corp Heteroarilaminosulfonamidas de 6 membros para tratamento de doenças e condições mediadas por atividade deficiente de cftr
KR20220115829A (ko) 2019-11-12 2022-08-18 젠자임 코포레이션 결핍된 cftr 활성에 의해 매개된 병태를 치료하기 위한 5-원 헤테로아릴아미노설폰아미드
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CA3188787A1 (en) 2020-08-13 2022-02-17 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators

Also Published As

Publication number Publication date
JP2024050811A (ja) 2024-04-10
TWI828358B (zh) 2024-01-01
RS64018B1 (sr) 2023-03-31
SMT202300043T1 (it) 2023-03-17
US20220106331A1 (en) 2022-04-07
CN112004817A (zh) 2020-11-27
PT3752510T (pt) 2023-03-15
UA126304C2 (uk) 2022-09-14
HRP20230030T1 (hr) 2023-03-03
AU2019222758A1 (en) 2020-08-13
US20190248809A1 (en) 2019-08-15
PE20210454A1 (es) 2021-03-08
MX2020008268A (es) 2020-09-21
JP7214743B2 (ja) 2023-01-30
SA520412634B1 (ar) 2024-10-13
AU2019222758B2 (en) 2022-07-07
EP3752510B1 (en) 2022-12-07
TW201938566A (zh) 2019-10-01
CN117285547A (zh) 2023-12-26
BR112020015509A2 (pt) 2021-01-26
PL3752510T3 (pl) 2023-05-08
US11866450B2 (en) 2024-01-09
TW202304937A (zh) 2023-02-01
KR20200131240A (ko) 2020-11-23
UY38093A (es) 2019-10-01
MA51828A (fr) 2020-12-23
DOP2023000016A (es) 2023-02-28
CL2020002055A1 (es) 2021-03-19
MA51828B1 (fr) 2022-11-30
FI3752510T3 (fi) 2023-03-14
JP2021513967A (ja) 2021-06-03
CN112004817B (zh) 2023-06-23
IL276662A (en) 2020-09-30
US11066417B2 (en) 2021-07-20
GEP20237571B (en) 2023-11-27
IL294042A (en) 2022-08-01
EP4198037A1 (en) 2023-06-21
TWI780304B (zh) 2022-10-11
EA202091930A1 (ru) 2021-03-12
LT3752510T (lt) 2023-04-11
KR102482271B1 (ko) 2022-12-27
JOP20200178A1 (ar) 2022-10-30
US20240368189A1 (en) 2024-11-07
CA3088577A1 (en) 2019-08-22
ZA202004357B (en) 2023-12-20
DK3752510T3 (da) 2023-01-16
AU2022231721A1 (en) 2022-10-06
AR114254A1 (es) 2020-08-12
WO2019161078A1 (en) 2019-08-22
ES2939775T3 (es) 2023-04-26
MD3752510T2 (ro) 2023-06-30
JP2022126802A (ja) 2022-08-30
EP3752510A1 (en) 2020-12-23
ECSP20053845A (es) 2020-12-31
HUE061046T2 (hu) 2023-05-28
IL276662B (en) 2022-08-01
SG11202006614VA (en) 2020-08-28
AU2022231721B2 (en) 2024-09-19
SI3752510T1 (sl) 2023-03-31

Similar Documents

Publication Publication Date Title
ZA202004357B (en) Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them
SA519401446B1 (ar) مُعدِّل منظم التوصيل عبر الأغشية للتليف الكيسي، تركيبات صيدلية، طرق علاج، وعملية لتحضير المُعدِّل
SA519401947B1 (ar) مُعدِّل منظم التوصيل عبر الأغشية للتليف الكيسي، تركيبات صيدلية، طرق علاج، وعملية لتحضير المُعدِّل
MX2022001828A (es) Formas cristalinas de moduladores del regulador de conductancia transmembrana de la fibrosis quistica (cftr).
ZA202107711B (en) Cystic fibrosis transmembrane conductance regulator modulating agents
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
MX2020002806A (es) Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso.
NZ763365A (en) Crystalline forms and compositions of cftr modulators
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
EP4484440A3 (en) Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
TN2018000175A1 (en) Indane derivatives as mglur7 modulators
ZA202203108B (en) Indole carboxamide compounds and use thereof for the treatment of mycobacterial infections
NZ754805B2 (en) Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CR20190211A (es) Modulador del regulador de conductancia de transmembrana de fibrosis quistica, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador
EA201990850A1 (ru) Модулятор муковисцидозного трансмембранного регулятора проводимости, фармацевтические композиции, способы лечения и способы получения модулятора